BioSpace News Archive

Sanofi announced that its Q1 2022 Memorandum for modelling purposes is available on the “Investors” page of the company’s website:.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock.

Ascletis Pharma Inc. announces the completion of patient enrollment in the Phase II clinical trial of ASC42 for chronic hepatitis B indication.

Trevena, Inc. today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, prior to the market open on Thursday, March 31st, 2022.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the fourth quarter and full year ended December 31, 2021.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12th, 2022.

Sol-Gel Technologies, Ltd. today announced financial results for the full year ended December 31, 2021, and provided recent corporate updates.

CareDx, Inc. today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA.

Cognition Therapeutics, Inc. today reported financial results for the year ended December 31, 2021 and provided recent business updates.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 14,800 shares of its common stock with an exercise price of $4.90, which is equal to the closing price of Gritstone’s common stock on March 17, 2022, the grant date of the awards.